Literature DB >> 6089556

Enalapril worldwide experience.

R O Davies, J D Irvin, D K Kramsch, J F Walker, F Moncloa.   

Abstract

Overall, the worldwide experience on enalapril to date is very encouraging. The drug produces good to excellent responses in 54 to 66 percent of patients with essential hypertension and is at least as effective as either diuretics or beta blockers. The effects of enalapril compared with those of diuretics confirm that patients more dependent upon the renin-angiotensin system respond better. When hydrochlorothiazide is administered concomitantly with enalapril, almost all patients respond, with good long-term maintenance. In patients with severe hypertension, Blocadren or Aldomet may be added in addition to hydrochlorothiazide and will produce additional benefit. Enalapril attenuates the adverse metabolic effects of hydrochlorothiazide, particularly hypokalemia. Overall, although the efficacy of enalapril and that of captopril are similar, enalapril is better tolerated and does not appear to be associated with any significant occurrence of captopril-type side effects, particularly the skin rash and loss of taste. As expected, enalapril and other converting inhibitors may be associated with azotemia in patients with bilateral renovascular hypertension.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6089556     DOI: 10.1016/s0002-9343(84)80055-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  25 in total

Review 1.  Selective alpha 1-adrenoreceptor blockers in the treatment of hypertension: should we be using them more?

Authors:  M Ligueros; R Unwin; M Wilkins
Journal:  Clin Auton Res       Date:  1991-09       Impact factor: 4.435

Review 2.  ACE inhibitors in the prevention and therapy of diabetic nephropathy. What is their role?

Authors:  C C Kelleher
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  A need for new converting enzyme inhibitors?

Authors:  S G Ball; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-19

Review 4.  Drug therapy in childhood hypertension.

Authors:  L P Roy
Journal:  Indian J Pediatr       Date:  1988 May-Jun       Impact factor: 1.967

Review 5.  Safety profiles of the angiotensin-converting enzyme inhibitors.

Authors:  N J Warner; J E Rush
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 7.  Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction.

Authors:  R I Henkin
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 8.  Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety.

Authors:  F Moncloa; J A Sromovsky; J F Walker; R O Davies
Journal:  Drugs       Date:  1985       Impact factor: 9.546

Review 9.  The elderly patient. A special case for diuretic therapy.

Authors:  D E Hyams
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Renal effects of angiotensin converting enzyme inhibitors: nondiabetic chronic renal disease.

Authors:  J A Opsahl; P A Abraham; W F Keane
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.